Detalhe da pesquisa
1.
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study.
Breast Cancer Res Treat
; 199(1): 35-46, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36859649
2.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Lancet Oncol
; 23(7): 851-864, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35671774
3.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Lancet Oncol
; 21(3): 345-357, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32035020
4.
Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience.
Breast Cancer Res Treat
; 174(3): 731-740, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30656459
5.
Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Lancet Oncol
; 19(3): 323-336, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29433963
6.
Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer.
Clin Cancer Res
; 30(4): 895-903, 2024 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38078899
7.
Single domain intracellular antibodies from diverse libraries: emphasizing dual functions of LMO2 protein interactions using a single VH domain.
J Biol Chem
; 286(5): 3707-16, 2011 Feb 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-20980262
8.
Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression.
Breast
; 64: 100-111, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35636341
9.
Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer.
Breast
; 66: 69-76, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36194950
10.
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
J Clin Oncol
; 40(28): 3246-3256, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35584336
11.
Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer.
Clin Cancer Res
; 27(21): 5818-5827, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34380637
12.
The AusPSIs: the Australian version of the Agency of Healthcare Research and Quality patient safety indicators.
Aust Health Rev
; 33(2): 334-41, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19563325